Literature DB >> 17068073

Effects of dietary management of phenylketonuria on long-term cognitive outcome.

Shelley Channon1, Galya Goodman, Sally Zlotowitz, Caroline Mockler, Philip J Lee.   

Abstract

BACKGROUND: Phenylketonuria (PKU) is associated with dopaminergic depletion in the dorsolateral prefrontal cortex and abnormalities of myelination. Both mechanisms may lead to deficits in cognitive functioning. Studies of cognitive outcome in children treated with PKU at an early stage have suggested that there are benefits in remaining on diet into adolescence. AIM: To assess the nature and extent of any cognitive deficits in adults treated at an early stage with PKU who had discontinued their diets in adolescence.
METHOD: 25 patients (aged 18-38 years) who were diagnosed early and had discontinued their diets in adolescence were compared with 25 adults (aged 18-38 years) with PKU on continuous diet, and with a healthy control group (n = 45).
RESULTS: The groups differed significantly on accuracy (p = 0.007) and speed (p = 0.001) of performance on an n-back working memory task and on speed of performance (p = 0.001) on a flanker inhibitory task, but not on flanker accuracy, object alternation learning or perceptual judgement tasks (all p>0.05). The off-diet group performed significantly below the on-diet group on n-back accuracy (p = 0.007) and flanker speed (p = 0.05), and significantly below the control group on n-back speed (p = 0.002) and flanker speed (p = 0.001).
CONCLUSION: The findings suggest that although discontinuing diet in adolescence appears disadvantageous compared with remaining on continuous diet, any deficits are relatively subtle.

Entities:  

Mesh:

Year:  2006        PMID: 17068073      PMCID: PMC2083434          DOI: 10.1136/adc.2006.104786

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  24 in total

Review 1.  Chemical neuromodulation of frontal-executive functions in humans and other animals.

Authors:  T W Robbins
Journal:  Exp Brain Res       Date:  2000-07       Impact factor: 1.972

2.  Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria.

Authors:  D A White; M J Nortz; T Mandernach; K Huntington; R D Steiner
Journal:  Neuropsychology       Date:  2001-04       Impact factor: 3.295

3.  Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria.

Authors:  Desirée A White; Marsha J Nortz; Tammy Mandernach; Kathleen Huntington; Robert D Steiner
Journal:  J Int Neuropsychol Soc       Date:  2002-01       Impact factor: 2.892

Review 4.  The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory.

Authors:  S C J Huijbregts; L M J de Sonneville; F J van Spronsen; R Licht; J A Sergeant
Journal:  Neurosci Biobehav Rev       Date:  2002-10       Impact factor: 8.989

5.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

6.  Executive functioning, memory, and learning in phenylketonuria.

Authors:  Shelley Channon; Elaine German; Cristina Cassina; Philip Lee
Journal:  Neuropsychology       Date:  2004-10       Impact factor: 3.295

7.  Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria.

Authors:  M Luciana; J Sullivan; C A Nelson
Journal:  Child Dev       Date:  2001 Nov-Dec

8.  Intelligence and quality of dietary treatment in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

Review 9.  A prefrontal dysfunction model of early-treated phenylketonuria.

Authors:  M C Welsh
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Material-dependent and material-independent selection processes in the frontal and parietal lobes: an event-related fMRI investigation of response competition.

Authors:  Eliot Hazeltine; Silvia A Bunge; Michael D Scanlon; John D E Gabrieli
Journal:  Neuropsychologia       Date:  2003       Impact factor: 3.139

View more
  25 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Neurological improvement following reinstitution of a low phenylalanine diet after 20 years in established phenylketonuria.

Authors:  M S Anwar; B Waddell; J O'Riordan
Journal:  BMJ Case Rep       Date:  2013-07-12

Review 3.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

4.  Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU).

Authors:  M Huemer; B Simma; D Mayr; D Möslinger; A Mühl; I Schmid; H Ulmer; O A Bodamer
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

5.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

6.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

7.  A cross-sectional study of docosahexaenoic acid status and cognitive outcomes in females of reproductive age with phenylketonuria.

Authors:  Sarah H L Yi; Julie A Kable; Marian L Evatt; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

Review 8.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

9.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.